Bayer And Onyx Initiate Phase 3 Trial Of Nexavar In Patients With Non-Responsive Thyroid Cancer

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer. This Phase 3 trial was started based on the results from Phase 2 clinical trials evaluating Nexavar in patients with advanced thyroid cancer.